接受常规双功超声筛查的静脉血栓栓塞高危创伤患者肺栓塞更少:一项前瞻性随机试验
该单中心前瞻性随机试验于2017年3月至2019年9月纳入风险评定量表评分≥5的创伤患者1989例,随机分为双下肢双功超声监测组(第1、3、7天及住院期间每周一次,995例)与不监测组(994例)。监测组住院期间肺栓塞显著少于不监测组(1例[0.1%] vs 9例[0.9%],p=0.01),但住院期间膝下深静脉血栓(124例[12.5%] vs 8例[0.8%],p<0.001)和膝上深静脉血栓(19例[1.9%] vs 8例[0.8%],p=0.05)更多。90天肺栓塞、深静脉血栓及全因死亡率无差异。作者认为常规筛查发现的深静脉血栓增多主要反映监测偏倚,主要见于远端深静脉血栓。
要点
- 风险评定量表评分≥5的创伤患者随机接受双下肢双功超声监测(第1、3、7天及住院期间每周一次)者住院期间肺栓塞1例(0.1%),不监测组9例(0.9%),p=0.01。
- 监测组住院期间膝下深静脉血栓124例(12.5%)多于不监测组8例(0.8%),p<0.001;膝上深静脉血栓19例(1.9%)多于8例(0.8%),p=0.05。
- 90天肺栓塞、深静脉血栓及全因死亡率两组无差异。
- 作者认为常规筛查检出的深静脉血栓增多主要反映监测偏倚,且主要见于远端深静脉血栓。
- 作者认为需要更大规模试验进一步明确高危创伤人群中常规双功超声筛查与静脉血栓栓塞结局的关系。
适用人群与场景
- 2017年3月至2019年9月收治于单一一级创伤中心的创伤患者,风险评定量表评分≥5。
- 共筛查3236例创伤科住院患者,随机1989例中高危患者(超声组995例,不超声组994例);平均±标准差年龄62±20.1岁,损伤严重度评分14±9.7,风险评定量表7.1±2.4,97%为钝性创伤。
- 所有患者均按既定机构方案接受静脉血栓栓塞预防和管理的标准治疗。
处置流程与药物剂量
- 超声组:住院第1、3、7天及住院期间每周行双下肢双功超声监测。
- 不超声组:不进行常规双功超声监测。
- 两组均按既定机构方案接受静脉血栓栓塞预防和管理的标准治疗。
研究设计与关键结果
- 研究类型:前瞻性随机试验;单中心;随机1989例(超声组995例,不超声组994例);人群为风险评定量表评分≥5的创伤患者。
- 住院期间肺栓塞:超声组1例(0.1%)vs 不超声组9例(0.9%),p=0.01。
- 住院期间膝下深静脉血栓:超声组124例(12.5%)vs 不超声组8例(0.8%),p<0.001。
- 住院期间膝上深静脉血栓:超声组19例(1.9%)vs 不超声组8例(0.8%),p=0.05。
- 90天肺栓塞、深静脉血栓及全因死亡率两组无差异。
- 两组人口学特征和静脉血栓栓塞危险因素无差异。
证据类型、等级与局限
- 证据类型:前瞻性随机试验;证据等级:治疗/临床管理,II级。
- 局限:作者指出常规筛查检出的深静脉血栓增多主要反映监测偏倚,主要见于远端深静脉血栓;作者认为需要更大规模试验进一步明确高危创伤人群中常规双功超声筛查与静脉血栓栓塞结局的关系。
对床旁实践的改变
- 在高危创伤患者(风险评定量表评分≥5)中,实施选择性常规双功超声方案与住院期间肺栓塞显著减少相关(0.1% vs 0.9%,p=0.01)。
- 常规筛查会检出更多深静脉血栓(膝下12.5% vs 0.8%,p<0.001;膝上1.9% vs 0.8%,p=0.05),但作者认为这一增多主要反映监测偏倚,且主要见于远端深静脉血栓。
- 90天肺栓塞、深静脉血栓及全因死亡率未见差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although guidelines are established for the prevention and management of venous thromboembolism (VTE) in trauma, no consensus exists regarding protocols for the diagnostic approach. We hypothesized that at-risk trauma patients who undergo duplex ultrasound (DUS) surveillance for lower extremity deep venous thrombosis (DVT) will have a lower rate of symptomatic or fatal pulmonary embolism (PE) than those who do not undergo routine surveillance.
METHODS: Prospective, randomized trial between March 2017 and September 2019 of trauma patients admitted to a single, level 1 trauma center, with a risk assessment profile score of ≥5. Patients were randomized to receive either bilateral lower extremity DUS surveillance on days 1, 3, and 7 and weekly during hospitalization ultrasound group (US) or no surveillance no ultrasound group (NoUS). Rates of in-hospital and 90-day DVT and PE were reported as was DVT propagation and all-cause mortality. Standard care for the prevention and management of VTE per established institutional protocols was provided to all patients.
RESULTS: A total of 3,236 trauma service admissions were screened, and 1,989 moderate- and high-risk patients were randomized (US, 995; NoUS, 994). The mean ± SD age was 62 ± 20.1 years, Injury Severity Score was 14 ± 9.7, risk assessment profile was 7.1 ± 2.4, and 97% suffered blunt trauma. There was no difference in demographics or VTE risk factors between the groups. There were significantly fewer in-hospital PE in the US group than the NoUS group (1 [0.1%] vs. 9 [0.9%], p = 0.01). The US group experienced more in-hospital below-knee DVTs (124 [12.5%] vs. 8 [0.8%], p < 0.001) and above-knee DVTs (19 [1.9%] vs. 8 [0.8%], p = 0.05). There was no difference in 90-day PE or DVT, or overall mortality.
CONCLUSION: The implementation of a selective routine DUS protocol was associated with significantly fewer in-hospital PE. More DVTs were identified with routine screening; however, surveillance bias appears to exist primarily with distal DVT. Larger trials are needed to further characterize the relationship between routine DUS screening and VTE outcomes in the high-risk trauma population.
LEVEL OF EVIDENCE: Therapeutic/care management, level II.
参考来源
- Kay AB, Morris DS, Woller SC, et al. Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial. J Trauma Acute Care Surg. 2021. PMID: 33560104. doi:10.1097/TA.0000000000003104
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。